Scholarlink

Objective <p>Toll-like receptor 7 (TLR7) recognizes single-stranded RNA and plays a crucial role in initiating immune responses against viral pathogens. This study characterizes SZU-106, a recently developed Toll-like receptor 7 (TLR7) agonist, focusing on its physicochemical and biological properties as key determinants for assessing its suitability for drug product development.</p> Methods <p>Distribution coefficients (LogD) of SZU-106 were determined in silico and confirmed experimentally by the shake-flask method. Stress stability tests were performed by incubation at different pH conditions using temperatures between room temperature and 60°C. HPLC ESI–MS/MS analysis was applied to determine the main degradation products. Cytotoxicity tests with different reporter cell lines allowed excluding TRL7-mediated as well as unspecific cytotoxicity in THP-1 monocytes and macrophages.</p> Results <p>The analysis of distribution coefficients conducted at pH 5.6 and 7.4 confirmed the predominantly hydrophilic nature of SZU-106. Stress stability testing revealed the stability of SZU-106 in neutral aqueous solutions, while rapid degradation was noted under acidic and basic conditions with rate constants of 2.21·10–3 d-1 to 0.39&#xa0;h-1. HPLC ESI–MS/MS analysis showed that SZU-106 primarily degrades via hydrolytic cleavage of its amide bonds, with four major degradation products identified and structurally characterized. Cytotoxicity assays with THP-1 monocytes and differentiated macrophages at increasing drug concentrations (10 -1000&#xa0;µM) illustrated no off-target cytotoxicity and only mild, time-dependent, receptor-mediated effects in TLR7-overexpressing THP-1 cells at high SZU-106 concentrations.</p> Conclusions <p>This evaluation of SZU-106 supports its further development as a therapeutic TLR7 agonist, with formulation strategies representing the next stage for drug development.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Physicochemical and Biological Characterization of the TLR7 Agonist SZU-106

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月26日

查看全文
  • Martin Herbst,
  • Johannes Kipp,
  • Sonja M. Kessler,
  • Christian Wischke

摘要

Objective

Toll-like receptor 7 (TLR7) recognizes single-stranded RNA and plays a crucial role in initiating immune responses against viral pathogens. This study characterizes SZU-106, a recently developed Toll-like receptor 7 (TLR7) agonist, focusing on its physicochemical and biological properties as key determinants for assessing its suitability for drug product development.

Methods

Distribution coefficients (LogD) of SZU-106 were determined in silico and confirmed experimentally by the shake-flask method. Stress stability tests were performed by incubation at different pH conditions using temperatures between room temperature and 60°C. HPLC ESI–MS/MS analysis was applied to determine the main degradation products. Cytotoxicity tests with different reporter cell lines allowed excluding TRL7-mediated as well as unspecific cytotoxicity in THP-1 monocytes and macrophages.

Results

The analysis of distribution coefficients conducted at pH 5.6 and 7.4 confirmed the predominantly hydrophilic nature of SZU-106. Stress stability testing revealed the stability of SZU-106 in neutral aqueous solutions, while rapid degradation was noted under acidic and basic conditions with rate constants of 2.21·10–3 d-1 to 0.39 h-1. HPLC ESI–MS/MS analysis showed that SZU-106 primarily degrades via hydrolytic cleavage of its amide bonds, with four major degradation products identified and structurally characterized. Cytotoxicity assays with THP-1 monocytes and differentiated macrophages at increasing drug concentrations (10 -1000 µM) illustrated no off-target cytotoxicity and only mild, time-dependent, receptor-mediated effects in TLR7-overexpressing THP-1 cells at high SZU-106 concentrations.

Conclusions

This evaluation of SZU-106 supports its further development as a therapeutic TLR7 agonist, with formulation strategies representing the next stage for drug development.

Graphical Abstract